Related Experiment Videos
Serum free thiols in chronic heart failure
Anne M Koning1, Wouter C Meijers2, Andreas Pasch3
1Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Pharmacological Research
|July 6, 2016
Summary
Serum free thiols may indicate better heart failure (HF) prognosis. Higher levels correlated with younger patients, better kidney function, and improved survival, suggesting redox status as a potential therapeutic target.
Area of Science:
- Cardiology
- Biochemistry
- Oxidative Stress Research
Background:
- Oxidative stress is central to heart failure (HF) pathophysiology.
- Circulating free thiols reflect systemic redox status due to their susceptibility to oxidation.
- Free thiols represent a potential therapeutic target for HF management.
Purpose of the Study:
- To investigate the association between serum free thiol levels and clinical/outcome parameters in stable chronic heart failure patients.
- To explore the potential of serum free thiols as a prognostic biomarker in heart failure.
Main Methods:
- Serum free thiol concentrations were measured in 101 stable chronic heart failure patients.
- Measurements were adjusted for total serum protein.
- Associations with clinical characteristics, disease severity markers (NT-proBNP, PTH, eGFR, cholesterol), rehospitalisation rates, and patient survival were analyzed.
Main Results:
- Mean serum free thiol concentration was 3.6±0.5μM/g protein.
- Above-average free thiol levels were linked to younger age, better renal function (eGFR), lower NT-proBNP and PTH, and higher cholesterol.
- Higher free thiol levels showed a significant association with decreased rehospitalisation and increased survival (HR 0.27).
Conclusions:
- Serum free thiols are favorably associated with markers of HF severity and prognosis.
- These associations suggest that redox status, reflected by free thiols, plays a role in HF pathophysiology.
- Further prospective studies are warranted to confirm these findings and explore therapeutic modulation of free thiols for improved HF outcomes.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
511
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511
01:29Heart Failure II: Pathophysiology
1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
01:26Heart Failure III: Clinical Manifestations
797
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
797
01:30Heart Failure V: Medical Management
478
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
715
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
715
01:17Pathophysiology of Heart Failure
4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K